Open AccessPharmacogenetic evaluation of ABCB1, Cyp2C9, Cyp2C19 and methylene tetrahydrofolate reductase polymorphisms in teratogenicity of anti-epileptic drugs in women with epilepsy
Author(s) -
Manna Jose,
Moinak Banerjee,
Anila Mathew,
Tashi Bharadwaj,
Neetha N Vijayan,
Sanjeev V Thomas
Publication year - 2014
Publication title -
annals of indian academy of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.427
H-Index - 31
eISSN - 1998-3549
pISSN - 0972-2327
DOI - 10.4103/0972-2327.138475
Subject(s) - cyp2c19 , methylenetetrahydrofolate reductase , medicine , pharmacogenetics , cyp2c9 , genotype , epilepsy , pharmacology , gastroenterology , anesthesia , genetics , metabolism , gene , psychiatry , cytochrome p450 , biology
Pregnancy in women with epilepsy (WWE) who are on anti-epileptic drugs (AEDs) has two- to three-fold increased risk of fetal malformations. AEDs are mostly metabolized by Cyp2C9, Cyp2C19 and Cyp3A4 and transported by ABCB1. Patients on AED therapy can have folate deficiency. We hypothesize that the polymorphisms in ABCB1, Cyp2C9, Cyp2C19 and methylene tetrahydrofolate reductase (MTHFR) might result in differential expression resulting in differential drug transport, drug metabolism and folate metabolism, which in turn may contribute to the teratogenic impact of AEDs.